We’ve achieved some exciting IP milestones for Calla Lily Clinical Care; making strong progress in building a robust IP strategy and IP portfolio to protect and advance our innovations in women’s health.

💥 China Patent Grant for our Drug Delivery Device 🌏
At long last, one of our vaginal drug delivery applications in China has been granted (ZL202080032097.8) — a significant milestone in our global IP strategy. With declining birthrates in China, Japan, Korea and Singapore 📉 , the need for technologies that support IVF and miscarriage prevention has never been more urgent. We now have granted patents in *all* of these key markets, further solidifying our presence in Asia.

💥 UK Patent Grant for our Manufacturing Innovation 🌍
During the last year we have also secured a UK patent (GB2590903) covering our proprietary joining technology— a critical innovation in how our device integrates multiple component materials. I still recall the in-depth discussions with our technical team and IP advisors debating which novel aspects of our manufacturing should be patented and which to keep as trade secrets — an illustration that strategic IP decisions are never straightforward!

Developing a strong, defensible, and valuable IP portfolio is a complex, resource-intensive process. Congratulations to our team and external IP advisors— led by our CFO and head of IP, Stuart Prince—for driving these efforts forward! 💪